Toggle navigation
About Bio-Path
Leadership Team
Board of Directors
Scientific Advisory Board
Partnering Opportunities
Technology
Pipeline
Prexigebersen
BP1002
BP1003
Investors
Analyst Coverage
SEC Filings
Corporate Governance
Media
Press Releases
Events
Presentations & Publications
Careers
Contact Us
Press Releases
Press Releases
Events
Presentations & Publications
Our press releases
Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting
Dec 13 2021
Bio-Path Holdings Reports Third Quarter 2021 Financial Results
Nov 12 2021
Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021
Nov 5 2021
Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting
Nov 4 2021
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors
Oct 27 2021
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
Aug 24 2021
Bio-Path Holdings Reports Second Quarter 2021 Financial Results
Aug 13 2021
Bio-Path Holdings to Announce Second Quarter 2021 Financial Results on August 13, 2021
Aug 6 2021
Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003
Jun 22 2021
Bio-Path Holdings Reports First Quarter 2021 Financial Results
May 14 2021
Show More Posts
Loading...
Events
View Our Events
Presentations & Publications
View Our Publications
Delivering a Better Path for Cancer Patients.